Close Menu

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said after the close of the market Tuesday that it intends to offer 10 million shares of its common stock in an underwritten public offering.

Leerink Partners and Cantor Fitzgerald are acting as joint book-running managers for the offering, and LifeSci Capital is acting as co-manager. HTG expects to grant the underwriters a 30-day option to purchase up to an additional 1.5 million shares of its stock.

The shares are being offered by HTG pursuant to a shelf registration statement filed by the company in April 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

NPR reports that some insect pests are now becoming resistant to Bt crops.

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.